Aardvark Therapeutics, Inc.
AARD
$11.81
-$0.14-1.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 95.61% | 35.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.79% | 85.62% | |||
| Operating Income | -10.79% | -85.62% | |||
| Income Before Tax | -6.05% | -109.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.05% | -109.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.05% | -109.92% | |||
| EBIT | -10.79% | -85.62% | |||
| EBITDA | -10.83% | -85.56% | |||
| EPS Basic | 67.34% | -106.00% | |||
| Normalized Basic EPS | 67.22% | -109.48% | |||
| EPS Diluted | 67.34% | -106.00% | |||
| Normalized Diluted EPS | 67.22% | -109.48% | |||
| Average Basic Shares Outstanding | 224.75% | 1.90% | |||
| Average Diluted Shares Outstanding | 224.75% | 1.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||